×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
DMAC – diamedica therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
DMAC
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/16
08:06 am
dmac
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate [Yahoo! Finance]
Medium
Report
We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate [Yahoo! Finance]
11/15
08:04 am
dmac
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Medium
Report
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
11/13
04:47 pm
dmac
DiaMedica Therapeutics GAAP EPS of -$0.15 in-line [Seeking Alpha]
Low
Report
DiaMedica Therapeutics GAAP EPS of -$0.15 in-line [Seeking Alpha]
11/13
04:26 pm
dmac
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results [Yahoo! Finance]
Low
Report
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results [Yahoo! Finance]
11/13
04:20 pm
dmac
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
Low
Report
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
11/13
04:05 pm
dmac
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
Medium
Report
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
11/12
08:28 am
dmac
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference [Yahoo! Finance]
Low
Report
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference [Yahoo! Finance]
11/12
08:23 am
dmac
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
Low
Report
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2024
04:20 pm
dmac
diamedica therapeutics inc.
MISS
Report
-5.5%
diamedica therapeutics inc.
8/7/2024
04:15 pm
dmac
diamedica therapeutics inc.
BEAT
Report
3.1%
diamedica therapeutics inc.
5/8/2024
04:30 pm
dmac
diamedica therapeutics inc.
BEAT
Report
-5.2%
diamedica therapeutics inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/19
DiaMedica Therapeutics Announces Interim Results from Phase 1b Trial of DM199 in Chronic Kidney Disease Participants
26.7%
10/14 DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease 17.9%
12/17 DiaMedica Therapeutics Announces First Patient Dosed in REDUX Phase II Clinical Trial of DM199 for the Treatment of Chronic Kidney Disease 16.5%
1/3 Form 8-K DiaMedica Therapeutics For: Dec 27 11.8%
1/15 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.6%
8/19 Form 4 DiaMedica Therapeutics For: Aug 19 Filed by: Kellen Scott 8.6%
12/24 Hedge Funds Have Never Been More Bullish On DiaMedica Therapeutics Inc. (DMAC) [Yahoo! Finance News] 8.2%
11/14 DiaMedica Therapeutics Inc. 2019 Q3 - Results - Earnings Call Presentation [Seeking Alpha] 7.6%
3/26 DiaMedica Therapeutics to Present Research at National Kidney Foundation 2020 Spring Clinical Meetings Live Virtual Conference 7.2%
5/14 DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.8%
10/14 DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease 17.9%
12/17 DiaMedica Therapeutics Announces First Patient Dosed in REDUX Phase II Clinical Trial of DM199 for the Treatment of Chronic Kidney Disease 16.5%
1/3 Form 8-K DiaMedica Therapeutics For: Dec 27 11.8%
1/15 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.6%
8/19 Form 4 DiaMedica Therapeutics For: Aug 19 Filed by: Kellen Scott 8.6%
12/24 Hedge Funds Have Never Been More Bullish On DiaMedica Therapeutics Inc. (DMAC) [Yahoo! Finance News] 8.2%
11/14 DiaMedica Therapeutics Inc. 2019 Q3 - Results - Earnings Call Presentation [Seeking Alpha] 7.6%
3/26 DiaMedica Therapeutics to Present Research at National Kidney Foundation 2020 Spring Clinical Meetings Live Virtual Conference 7.2%
5/14 DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.8%
TOP News Decliners
8/13
DiaMedica Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update
-34.7%
11/28 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -13.7%
3/24 DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -12.7%
12/13 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -11.8%
11/13 DiaMedica Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update -8.6%
9/3 DiaMedica Therapeutics to Present at the 2019 Dougherty & Co. Institutional Investor Conference -7.4%
1/3 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.2%
7/16 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.0%
9/6 DiaMedica Therapeutics to Present at Lake Street’s 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019 -6.6%
2/11 Form 424B5 DiaMedica Therapeutics -5.8%
11/28 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -13.7%
3/24 DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -12.7%
12/13 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -11.8%
11/13 DiaMedica Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update -8.6%
9/3 DiaMedica Therapeutics to Present at the 2019 Dougherty & Co. Institutional Investor Conference -7.4%
1/3 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.2%
7/16 DiaMedica Therapeutics Inc (NASDAQ: DMAC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.0%
9/6 DiaMedica Therapeutics to Present at Lake Street’s 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019 -6.6%
2/11 Form 424B5 DiaMedica Therapeutics -5.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: